<DOC>
	<DOCNO>NCT01031030</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , methotrexate , fluorouracil , epirubicin hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give cyclophosphamide together methotrexate fluorouracil , , without epirubicin hydrochloride effective treating patient breast cancer remove surgery . PURPOSE : This randomized phase III trial compare three regimen cyclophosphamide give together methotrexate fluorouracil , without epirubicin hydrochloride , see well work treat woman undergone surgery breast cancer . ( Group III close new patient 12/7/2009 . )</brief_summary>
	<brief_title>Cyclophosphamide , Methotrexate , Fluorouracil , With Without Epirubicin Hydrochloride , Treating Women Who Have Undergone Surgery Breast Cancer ( Group III Closed New Patients 12/7/2009 )</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine impact adjuvant chemotherapy comprise epirubicin hydrochloride follow cyclophosphamide , methotrexate , fluorouracil versus cyclophosphamide , methotrexate , fluorouracil follow epirubicin hydrochloride versus cyclophosphamide , methotrexate , fluorouracil overall survival patient biologically aggressive , resectable , node-negative node-positive breast cancer . Secondary - To assess disease-free survival pattern relapse patient . - To assess tolerance toxicity treatment patient . - To determine quality life patient . - To verify effectiveness treatment different subgroup patient . - To collect , retrospectively , information expression tumor suppressor gene p53 , oncogene c-erbB-2 , bcl-2 protein involve apoptosis . ( exploratory ) OUTLINE : This multicenter study . Patients stratify accord center , lymph node status ( N0 vs N1-3 ) , estrogen receptor status ( negative v positive ) . Patients randomize 1 3 treatment arm . - Arm I : Beginning 4-6 week follow surgery , patient receive epirubicin hydrochloride IV day 1 . Treatment repeat every 3 week 4 course . Patients receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1-8 . Treatment repeat every 4 week 4 course . - Arm II : Beginning 4-6 week follow surgery , patient receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1-8 . Treatment repeat every 4 week 4 course . Patients receive epirubicin hydrochloride IV day 1 . Treatment repeat every 3 week 4 course . - Arm III ( close accrual 12/7/2009 ) : Beginning 4-6 week follow surgery , patient receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1-8 . Treatment repeat every 4 week 6 course . Patients estrogen receptor-positive disease receive tamoxifen daily 5 year complete chemotherapy . After completion study therapy , patient follow every 3 month 1 year , every 6 month 4 year , annually 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Underwent radical mastectomy , guadrantectomy , tumorectomy axillary node dissection within past 46 week Biologically aggressive disease At least 10 lymph node remove Nodenegative ( &gt; 1 cm , &gt; 2 cm histology favorable , esp . tubular carcinoma and/or prevalent intraductal component &gt; 50 % ) tumor OR nodepositive ( 13 ) tumor , meet follow criterion : High thymidinelabeling index ( &gt; 3 % ) Poorly differentiate tumor ( grade III ) High Sphase fraction ( &gt; 10 % flow cytometry ) High Ki67/MIB1 expression ( &lt; 20 % ) No bilateral breast cancer No T4a , inoperable T4b , T4c , T4d disease Any estrogen receptor status ( positive , negative , unknown ) No distant metastases PATIENT CHARACTERISTICS : Any menopause status WBC ≥ 3,500/mL ANC ≥ 1,500/mL Platelet count ≥ 120,000/mL AST ALT ≤ 1.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 mg/mL Bilirubin ≤ 1.5 time ULN Not pregnant Geographically accessible followup No prior breast cancer and/or cancer except carcinoma situ cervix basal cell skin cancer treat radical intent No significant alteration cardiovascular function No serious psychiatric disorder No impaired renal liver function PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>